Kevin S. Boyle, Sr

2021

In 2021, Kevin S. Boyle, Sr earned a total compensation of $4.6M as Chief Executive Officer at ZIOPHARM Oncology.

Compensation breakdown

Bonus$147,500
Option Awards$2,790,638
Salary$200,000
Stock Awards$1,435,000
Other$315
Total$4,573,753

Boyle received $2.8M in option awards, accounting for 61% of the total pay in 2021.

Boyle also received $147.5K in bonus, $200K in salary, $1.4M in stock awards and $315 in other compensation.

Rankings

In 2021, Kevin S. Boyle, Sr's compensation ranked 2,891st out of 12,415 executives tracked by ExecPay. In other words, Boyle earned more than 76.7% of executives.

ClassificationRankingPercentile
All
2,891
out of 12,415
77th
Division
Manufacturing
1,151
out of 5,505
79th
Major group
Chemicals And Allied Products
457
out of 2,375
81st
Industry group
Drugs
401
out of 2,096
81st
Industry
Pharmaceutical Preparations
269
out of 1,546
83rd
Source: SEC filing on April 25, 2023.

News

In-depth

You may also like